Loading the full library. You can read the first studies below.
How this library is organized
Studies default to publication date, newest first, not the date a summary was added. Choose Most relevant for human-first editorial reading order, not an effectiveness or quality ranking. Design, topic and intervention-candidate labels assist discovery; they are not formal appraisals. Result-direction and sample-size filters only use existing verified metadata; missing values are excluded when those filters are active. Study counts are publications, not unique trials or participants.
Human · Observational · 2026-10-12
A longitudinal cohort examined cardiac changes after continued or discontinued steroid use.
Population, studied exposure & key finding
- Population
- 70 men with steroid-use histories and 35 nonusing weightlifters returned for follow-up.
- Studied dose & duration
- Self-selected steroid use, cessation or continued abstinence; no standardized treatment regimen.
- Finding
- Continued users had ejection fraction 48 percent and indexed ventricular mass 119 g/m². Those stopping showed a six-percentage-point ejection-fraction improvement and 21 g/m² mass-index reduction.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-12
A crossover trial tested whether beetroot juice increased repetitions to failure.
Population, studied exposure & key finding
- Population
- Sixteen resistance-trained women.
- Studied dose & duration
- Juice with 12.8 mmol nitrate, placebo with 0.92 mmol, or no drink, 2.5 hours before bench and leg press at 60% of maximum.
- Finding
- Bench repetitions were 56.0 with nitrate versus 58.9 with placebo; leg-press repetitions were 79.3 versus 80.4. Differences were not significant. Exertion, heart rate, blood pressure and lactate also did not improve.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-09
A double-blind trial tested urolithin A effects on peripheral and brain vascular responses.
Population, studied exposure & key finding
- Population
- 50 middle-aged adults with obesity; 7 were lost to follow-up.
- Studied dose & duration
- Urolithin A 1000 mg versus placebo for 4 weeks.
- Finding
- The primary flow-mediated-dilation outcome and other peripheral vascular outcomes did not improve significantly. A secondary task-evoked brain-hemodynamic signal improved, while task performance remained unchanged.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Unclassified · 2026-10-09
An open-label extension followed weekly growth-hormone replacement.
Population, studied exposure & key finding
- Population
- 220 adults with GH deficiency who completed the parent trial.
- Studied dose & duration
- Weekly lonapegsomatropin for a 52-week extension after the 38-week parent trial. All received active treatment; exact doses were not in the abstract.
- Finding
- Body-composition improvements were maintained or improved relative to parent-trial baseline through up to 90 weeks. Injection-site reactions occurred in 5.1%, mild or moderate. Respiratory infections and headache were common events.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-08
NOPARK tested whether a NAD precursor improved early Parkinson disease outcomes.
Population, studied exposure & key finding
- Population
- 410 randomized participants; 393 in the primary analysis.
- Studied dose & duration
- Oral nicotinamide riboside 500 mg twice daily versus placebo for 52 weeks, alongside stable dopaminergic treatment.
- Finding
- The primary symptom score favored placebo: adjusted difference 2.72 points (95% CI 0.47–4.98), indicating greater worsening with NR. Four key secondary outcomes were null. Serious adverse events: 8.3% versus 14.1%.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-07
A randomized trial examined blood-cell mitochondrial and antioxidant markers.
Population, studied exposure & key finding
- Population
- Premenopausal women with overweight or obesity; sample size not specified in the abstract.
- Studied dose & duration
- Anhydrous betaine 3 g/day versus placebo for eight weeks.
- Finding
- Citrate-synthase protein concentration changed by 102.3 μg/mg protein more than placebo (95% CI 3.19–201.4), despite nonsignificant within-group changes. Catalase activity increased; other measured mitochondrial/redox markers did not clearly improve.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-07
A phase 2 trial tested a triple-receptor agonist for weight reduction.
Population, studied exposure & key finding
- Population
- 205 adults with overweight/obesity and no diabetes.
- Studied dose & duration
- Weekly subcutaneous UBT251 targets of 2, 4 or 6 mg versus placebo for 24 weeks; two starting schedules for the 4 mg target. Route confirmed in the registry.
- Finding
- Weight changed -19.7% to -13.6% across active groups, versus -2.0% with placebo. Gastrointestinal events were most frequent, generally mild or moderate.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-07
A crossover trial tested inhibition of fructose metabolism in fatty liver disease.
Population, studied exposure & key finding
- Population
- 15 participants with metabolic dysfunction-associated steatotic liver disease.
- Studied dose & duration
- Oral PF-06835919 300 mg daily versus placebo for six weeks per treatment period; route and dose verified in the trial registry.
- Finding
- Hepatic insulin sensitivity improved on the primary endpoint. Liver lipid, peripheral glucose disposal and nocturnal fat oxidation also improved. Body weight did not change.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-07
A pilot trial tested an orexin blocker for daytime sleep in shift workers.
Population, studied exposure & key finding
- Population
- 29 night-shift workers, including 28 women.
- Studied dose & duration
- One week at 5 mg, then two weeks at 5 or 10 mg lemborexant, versus placebo.
- Finding
- No significant placebo advantage for sleep duration, efficiency, quality or insomnia severity. Exploratory higher-dose findings did not beat placebo. No serious adverse events occurred in the active group.
Abstract summarized · Verified intervention · Summary quality not appraised
Human · Randomized trial · 2026-10-07
A randomized pilot tested behavioral-app support or medically tailored meals versus usual care after GLP-1 treatment stopped.
Population, studied exposure & key finding
- Population
- 39 adults with prior GLP-1-associated weight loss; 34 completed a final weigh-in.
- Studied dose & duration
- Four months of a Noom subscription, 10 tailored meals weekly, or provider-directed usual care.
- Finding
- Estimated weight gain was 10.75% with usual care, 3.60% with the app and 3.58% with meals. Adherence, satisfaction, diet quality and perceived health did not significantly differ. No harms were reported.
Full paper summarized · Verified intervention · Summary quality not appraised
Human · Sponsor announcement · Unclassified · 2026-10-07
Preliminary ZUPREME-2 results tested an amylin analog against placebo.
Population, studied exposure & key finding
- Population
- 220 adults with overweight/obesity and type 2 diabetes.
- Studied dose & duration
- Weekly subcutaneous petrelintide, with escalation, versus placebo for 28 weeks. Milligram targets were not disclosed.
- Finding
- Sponsor-reported weight loss was 7.4–9.2% versus 2.0%, using the efficacy estimand. Placebo-adjusted HbA1c reduction was 0.61–0.88 percentage points. GI-related discontinuation: 1.9% versus 1.7%.
Sponsor announcement summarized · Verified intervention · Summary quality not appraised
Human · Unclassified · 2026-10-01
A double-blind phase 3 trial compared survodutide with placebo for weight and glycemic outcomes.
Population, studied exposure & key finding
- Population
- 752 adults with type 2 diabetes and BMI of at least 27.
- Studied dose & duration
- Subcutaneous survodutide 3.6 mg or 6.0 mg once weekly, versus placebo, over 76 weeks.
- Finding
- For 3.6 mg, 6.0 mg, and placebo, respectively: weight changed -8.2%, -9.8%, and -3.9%; at least 5% weight loss occurred in 57.6%, 64.5%, and 35.1%. HbA1c fell 0.9, 0.8, and 0.2 percentage points. GI events occurred in 72.8%, 77.7%, and 38.6%, generally transient and mild to moderate.
Abstract summarized · Verified intervention · Summary quality not appraised